Further support for the use of mepolizumab to prevent lung function decline has been demonstrated by a Belgian severe asthma registry publication, which reported that treatment with anti-IL-5 biologic therapy as part of standard clinical care attenuated lung function decline in patients with severe asthma (27). The gene discussed is IL5; the disease is asthma.